Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies
This study is looking at how long red blood cells (RBCs) survive in people with sickle cell disease (SCD) and other inherited blood disorders like thalassemia. Researchers want to compare RBC survival in people who have not had a transplant to those who have had a bone marrow transplant. You would receive an infusion of your own red blood cells that have been labeled with biotin. The study aims to measure how many days these labeled RBCs can be detected in your body. This information will help doctors better understand these conditions and the effects of treatments. The study plans to enroll 100 participants.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 100 participants aged 18 to 100 years old.
- What's involved
- If you haven't had a transplant, you will have lab draws every two weeks until the biotin-labeled cells are no longer detected. If you have had a transplant, you will have lab draws every four weeks until week 12, then every two weeks until the biotin-labeled cells are no longer detected.
- Compensation
- Not stated in the trial record.
- Follow-up
- For participants without a transplant, follow-up involves lab draws every two weeks until biotin-labeled red blood cells are no longer detected. For participants post-transplant, follow-up involves lab draws every four weeks until week 12, then every two weeks until biotin-labeled red blood cells are no longer detected.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- John F Tisdale, M.D. · PRINCIPAL_INVESTIGATOR · National Heart, Lung, and Blood Institute (NHLBI)
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- To determine and compare red blood cell survival, by virtue of the mean number of days of detectable biotin-labeled RBCs, in participants with SCD and/or other hemoglobinopathies.Patients w/o transplant: lab draw every 2 weeks until biotin-labeled cells are no longer detected. Patients Post-transplant: lab draw every four weeks, until week 12. Lab draw every 2 weeks until biotin-labeled cells are no longer detected.
Enumeration of biotin-labeled RBCS (BioRBCs) will be performed by flow cytometry. F-cell and/or S-cell measurement will be done by flow cytometry. BioRBCs will be isolated from post-infusion blood samples using flow cytometry separation. The collected BioRBCs and the whole blood fraction will be analyzed by high performance liquid chromatography (HPLC) for hemoglobin content.